Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Esophagogastric Junction Adenocarcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 31, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

December 31, 2027

Conditions
Adenocarcinoma of Esophagogastric Junction
Interventions
DRUG

neoadjuvant Radiation plus SOX and PD-1 antibody

"Patients will be given the perioperative treatment as below once recruited:~First, neoradiation (5w) will be given: intensity modulated radiotherapy was given for tumors and high-risk lymphatic drainage areas. PD-1 antibody will be started concurrent the radiation for 2 cycles.~The neochemotherapy (SOX) and PD-1 antibody will be given for 2 cycles after 1 week since radiation completed ; Patients will rest 2 weeks after the last cycle of neochemotherapy, and evaluation will be performed during this time. And D2 surgery will be performed if resectable.~SOX and PD-1 antibody will be given q3w. Adjuvant chemotherapy: We advise starting 4 cycles of SOX regimen in 3-8w after surgery."

Trial Locations (1)

100044

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER